NCT05124743View on ClinicalTrials.gov

HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors

TerminatedOBSERVATIONAL
Enrollment

19

Participants

Timeline

Start Date

September 24, 2021

Primary Completion Date

August 14, 2023

Study Completion Date

August 14, 2023

Conditions
Ovarian CancerEndometrial CancerColo-rectal CancerCholangiocarcinomaNon-small Cell Lung CancerPancreas Cancer
Trial Locations (1)

77030

MD Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
collaborator

M.D. Anderson Cancer Center

OTHER

lead

Alaunos Therapeutics

INDUSTRY

NCT05124743 - HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors | Biotech Hunter | Biotech Hunter